Trials / Completed
CompletedNCT01135108
Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Spinal Cord Injury
A Double-Blind, Randomized, Placebo-Controlled, Single-Dose Two-Period Crossover Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion in Subjects With Spinal Cord Injury
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- KAI Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether KAI-1678 is effective in the treatment of pain associated with spinal cord injury.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo IV Infusion |
| DRUG | KAI-1678 | KAI-1678 IV Infusion |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2010-03-01
- Completion
- 2010-05-01
- First posted
- 2010-06-02
- Last updated
- 2025-09-02
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT01135108. Inclusion in this directory is not an endorsement.